Go back

EU drug R&D plans ‘extremely damaging’, claims industry

Drug company trade body suggests concerns around intellectual property will push R&D investment elsewhere

Plans to change EU rules on drug development would be “extremely damaging” to the bloc’s pharmaceutical industry, according to a trade body.

The European Commission is expected to publish its plans in the coming weeks, with expressed aims that include supporting innovation and ensuring medicines are accessible and affordable.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.